Ország: Malajzia
Nyelv: angol
Forrás: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
IMATINIB MESYLATE
EUCOGEN SDN BHD
IMATINIB MESYLATE
30 Tablets
Remedica Ltd.
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_ _ _ IMAREM FILM COATED TABLETS _ _ _IMATINIB_ (100MG AND 400MG) my-pl-imarem-fc-tabs-a9-trans Page 1 of 3 WHAT IS IN THIS LEAFLET 1. What Imarem is used for 2. How Imarem works 3. Before you use Imarem 4. How to use Imarem 5. While you are using it 6. Side effects 7. Storage and Disposal of Imarem 8. Product Description 9. Manufacturer 10. Product Registration Holder 11. Date of revision 12. Serial Number WHAT IMAREM IS USED FOR Imarem is used in the treatment for adult and children for: Chronic myeloid leukemia (CML) as well as for the treatment for CML in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. [Leukaemia is cancer of white blood cells. Chronic myeloid leukemia is a form of leukaemia in which certain abnormal white cells (myeloid cells) start growing out of control] Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. [Acute lymphoblastic leukaemia is a form of leukaemia in which certain abnormal white cells (named lymphoblasts) start growing out of control]. Imarem is also used in the treatment for adult for: Certain types of gastrointestinal stromal tumors (GIST). GIST are cancers of the stomach and the bowels. Relapsed or refractory Ph+ ALL as monotherapy. Myelodysplastic/myeloproliferative diseases (MDS/MPD). These are a group of blood disease in which some blood cells start growing out of control. Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα re- arrangement. These are blood diseases in which some blood cells named eosinophils start growing out of controls. Dermatofibrosarcoma protuberans (DFSP). DFSP is a cancer of the tissue beneath the skin in which some cells start growing out of control. Aggressive systemic mastocytosis (ASM). ASM is a rare condition where certain white blood cells (mast cells) build up in certain tissue and organs in the body. HOW IMAREM WORKS Imare Olvassa el a teljes dokumentumot
my-pi-imarem-fc-tabs-a5 page 1 of 13 PACKAGE INSERT 1. NAME OF THE PRODUCT Imarem 100 mg film-coated tablets Imarem 400 mg film-coated tablets 2. NAME AND STRENGTH OF ACTIVE INGREDIENT Imarem 100mg contains 100 mg imatinib (as mesilate). Imarem 400mg contains 400 mg imatinib (as mesilate). 3. DOSAGE FORM Film-coated tablet. Imarem, 100mg: Dark yellow to brownish-orange, round shaped, film-coated tablets with a breakline on one side and ‘100’ on the other side. Imarem, 400mg: Dark yellow to brownish-orange, ovaloid shaped, film-coated tablets with a breakline on one side and ‘400’ on the other side. 4. PHARMACOLOGICAL PROPERTIES PHARMACODYNAMICS Pharmacotherapeutic group: protein-tyrosine kinase inhibitor, ATC code: L01XE01 Mechanism of action Imatinib is a small molecule protein-tyrosine kinase inhibitor that potently inhibits the activity of the Bcr-Abl tyrosine kinase (TK), as well as several receptor TKs: Kit, the receptor for stem cell factor (SCF) coded for by the c-Kit proto-oncogene, the discoidin domain receptors (DDR1 and DDR2), the colony stimulating factor receptor (CSF-1R) and the platelet-derived growth factor receptors alpha and beta (PDGFR-alpha and PDGFR- beta). Imatinib can also inhibit cellular events mediated by activation of these receptor kinases. Pharmacodynamic effects Imatinib is a protein-tyrosine kinase inhibitor which potently inhibits the Bcr-Abl tyrosine kinase at the _in vitro_ , cellular and _in vivo _ levels. The compound selectively inhibits proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as fresh leukaemic cells from Philadelphia chromosome positive CML and patients and acute lymphoblastic leukaemia (ALL) patients.. my-pi-imarem-fc-tabs-a5 page 2 of 13 _In vivo _ the compound shows anti-tumour activity as a single agent in animal models using Bcr-Abl positive tumour cells. Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF Olvassa el a teljes dokumentumot